- Home
- ACI vs DVA Comparison
ACI vs DVA Comparison
Compare ACI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACI | DVA |
|---|---|---|
| Founded | 1860 | 1994 |
| Country | United States | United States |
| Employees | 270000 | N/A |
| Industry | Food Chains | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 13.5B |
| IPO Year | 2015 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ACI | DVA |
|---|---|---|
| Price | $13.60 | $216.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $22.00 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 7.7M | 660.6K |
| Earning Date | 04-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.40 | ★ 2.87 |
| Revenue | ★ $83,172,500,000.00 | $13,643,069,000.00 |
| Revenue This Year | $0.68 | $3.85 |
| Revenue Next Year | $1.47 | $3.07 |
| P/E Ratio | ★ $34.40 | $74.31 |
| Revenue Growth | 3.46 | ★ 6.46 |
| 52 Week Low | $13.31 | $101.00 |
| 52 Week High | $22.78 | $215.33 |
Technical Indicators
Market Signals| Indicator | ACI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 72.97 |
| Support Level | N/A | $189.09 |
| Resistance Level | $17.74 | N/A |
| Average True Range (ATR) | 0.51 | 5.18 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 8.67 | 98.21 |
Price Performance
Historical ComparisonAbout ACI Albertsons Companies Inc.
Albertsons Companies Inc is a food and drug retailer in United States. The company operate in well known banners including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, ACME, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, Balducci's Food Lovers Market, and others.
About DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.